Importantly, the GR and the H1 receptor are the targets of the largest number of drugs currently approved for clinical treatment.5 The combination of a synthetic glucocorticoid and an antihistamine is commonly administered in allergic rhinitis and atopic dermatitis.6, 7 Furthermore, coadministration of the antihistamine azelastine and the synthetic glucocorticoid mometasone synergistically ameliorated allergic inflammation in a murine model of allergic rhinitis.8 Therefore, coadministration therapies could lead to the design of new strategies to treat inflammation‐associated diseases. This evidence concerns the gene NR3C1 and allergic rhinitis.